Silexion Therapeutics Corp (NASDAQ:SLXN) shares, rose in value, with the stock price up by 30.63% to the previous day’s close as strong demand from buyers drove the stock to $1.45.
Actively observing the price movement in the last trading, the stock closed the session at $1.11. Referring to stock’s 52-week performance, its high was $122.02, and the low was $0.57. On the whole, SLXN has fluctuated by -7.64% over the past month.
With the market capitalization of Silexion Therapeutics Corp currently standing at about $12.20 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
The stock’s technical analysis shows that the price of SLXN currently trading nearly 25.36% and -4.27% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.92, while the 7-day volatility ratio is showing 18.49% which for the 30-day chart, stands at 20.69%. Furthermore, Silexion Therapeutics Corp (SLXN)’s beta value is 0.08, and its average true range (ATR) is 0.30.
A comparison of Silexion Therapeutics Corp (SLXN) with its peers suggests the former has fared considerably weaker in the market. SLXN showed an intraday change of 30.63% in last session, and over the past year, it shrunk by -98.44%%.
Data on historical trading for Silexion Therapeutics Corp (NASDAQ:SLXN) indicates that the trading volumes over the past 3 months, they’ve averaged 13.12 million. According to company’s latest data on outstanding shares, there are 8.41 million shares outstanding.
Nearly 19.06% of Silexion Therapeutics Corp’s shares belong to company insiders and institutional investors own 7.03% of the company’s shares. The stock has fallen by -27.86% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLXN stock heading into the next quarter.
